All
FDA Panel Advises Against Approval of Rociletinib in Lung Cancer
April 12th 2016FDA’s Oncologic Drugs Advisory Committee (ODAC) ultimately voted against the accelerated approval of rociletinib for patients with metastatic EGFR T790M–mutated non–small cell lung cancer (NSCLC) who have previously received an EGFR-targeted therapy.
Team-Based Approach Crucial in Addressing Palliative Care
April 7th 2016A session at the 2016 National Comprehensive Cancer Network (NCCN) Annual Conference opened today with a spotlight on finding more effective ways to encourage and deliver palliative care services across a variety of settings in oncology.